Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12321143 | 0.91 | HTR3A (0.61) | HTR3AJAK3SLC18A3SIGMAR1 | |
| SCHEMBL381572 | 0.88 | SLC18A3 (0.59) | KCNH2HTR2AHTR2CHTR3AJAK3 | |
| SCHEMBL4280 | 0.88 | SLC18A3 (0.59) | KCNH2HTR2AHTR2CHTR3AJAK3 | |
| SCHEMBL383031 | 0.88 | SLC18A3 (0.59) | KCNH2HTR2AHTR2CHTR3AJAK3 | |
| Benzene SCHEMBL28198364 | 0.88 | SLC18A3 (0.59) | KCNH2HTR2AHTR2CHTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL31233227 | 0.86 | DRD2 (0.57) | KCNH2HTR2AHTR2CHTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL1765272 | 0.86 | DRD2 (0.57) | KCNH2HTR2AHTR2CHTR3AJAK3 | |
| SCHEMBL21425192 | 0.84 | DRD2 (0.60) | KCNH2HTR2AHTR2CHPGDSDRD2 | |
| SCHEMBL22778230 | 0.84 | HTR3A (0.73) | KCNH2HTR3ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL22778149 | 0.84 | KCNH2 (0.55) | KCNH2HTR2AHTR2CHTR3ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | claimed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-12115154-B2 | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) | SRX CARDIO, LLC (US) | 2024-10-15 | — | — | US | disclosed |
| US-20220267269-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO LLC (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| EP-3983392-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX Cardio, LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206843-A | Compounds for modulating proprotein convertase subtilisin/Kexin type 9(PCSK9) | SRX心脏有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3778588-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2019185046-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | 上海美悦生物科技发展有限公司 | 2019-10-03 | — | — | WO | disclosed |
| US-20110212080-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212080-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | SLC14A1, LPXN, UBXN1 | KCNH2 3378/4885HTR2A 4804/4885HTR2C 4800/4885 |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | KCNH2 4801/4885HTR2A 3413/4885HTR2C 3722/4885 |
| US-12115154-B2 | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | KCNH2 4801/4885HTR2A 3413/4885HTR2C 3722/4885 |
| US-20220267269-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | KCNH2 4801/4885HTR2A 3413/4885HTR2C 3722/4885 |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | F2, PCSK9, F9 | KCNH2 2362/4885HTR2A 4534/4885HTR2C 4410/4885 |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | F2, PCSK9, F9 | KCNH2 2362/4885HTR2A 4534/4885HTR2C 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.